Enclomiphene Online Prescription. 2026 Provider Comparison
Medication evidence and practical access information. We have no verified affiliate offer for this exact medication; the guide below is informational, not a provider availability claim.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
No verified affiliate offer for this medication
This means we have not verified a supplied affiliate link to a page offering this exact medication—not that the medication is unavailable everywhere. We do not substitute another treatment or a general provider homepage.
Enclomiphene citrate is the trans-isomer of clomiphene, prescribed off-label as a fertility-preserving alternative to testosterone replacement therapy in men with secondary hypogonadism. The mechanism is the inverse of TRT: rather than replacing testosterone from outside the body, enclomiphene removes the estrogen-mediated negative feedback that suppresses LH and FSH, which in turn signals the testes to produce more endogenous testosterone while maintaining spermatogenesis. The catch: enclomiphene has never been FDA-approved as a finished drug product. Repros Therapeutics' Phase 3 program (the ZA-203 and ZA-204 trials) hit primary endpoints but the company withdrew its NDA in 2016 after FDA disagreement over the regulatory pathway. Today it reaches patients only through 503A and 503B compounding pharmacies. Pricing typically lands at $60–$150/month, well below most TRT programs, and roughly eight platforms in our network include it on their formularies.
A selective estrogen receptor modulator (SERM) and the trans-isomer of clomiphene citrate. By antagonising estrogen receptors in the hypothalamus, enclomiphene disinhibits GnRH pulsatility, which raises LH and FSH and drives testicular Leydig cells to produce more testosterone. The trans-isomer alone is the bioactive component; clomiphene's cis-isomer (zuclomiphene) accumulates in tissue with a half-life measured in weeks and contributes to the mood and visual side-effects that gave Clomid its mixed reputation in men's health.
Men with secondary hypogonadism, low testosterone driven by inadequate pituitary signalling rather than testicular failure, who want to preserve fertility or testicular volume. Best fit: men in their 20s–40s with not-yet-completed family plans, men whose initial labs show low testosterone with low or low-normal LH/FSH, and men who want to avoid the lifelong dependency profile of exogenous TRT. Poor fit: men with primary hypogonadism (high LH/FSH), men who have already failed clomiphene, and men needing aggressive testosterone elevation for symptom relief.
Typical starting dose is 12.5–25 mg/day orally; some clinicians use a 25 mg every-other-day schedule. Response should be evaluated at 6–8 weeks with total testosterone, free testosterone, LH, FSH, and a sensitive estradiol assay. Expect testosterone to rise into the 400–700 ng/dL range, a lower ceiling than TRT can deliver but typically enough for symptom resolution. Side-effect profile is dominated by mood changes, mild visual disturbances (rare, usually reversible), and occasional gynecomastia from rising estradiol. Compounded pricing runs $60–$150/mo, with consult fees on top depending on platform.
Verified Offers for enclomiphene
What the Studies Actually Show
Enclomiphene is not FDA-approved and has not been studied in the same scale of pivotal trials as approved TRT formulations. The figures below come from Phase 2/3 clinical studies and published peer-reviewed literature on the trans-isomer's pharmacology.
| Endpoint | Finding |
|---|---|
| Testosterone increase (25 mg/day, 6 weeks)1 | Mean total testosterone rose to ~604 ng/dL from hypogonadal baseline — within the normal adult male range |
| Fertility preservation1 | Unlike exogenous testosterone, enclomiphene stimulates the HPG axis (LH and FSH rise), maintaining spermatogenesis. Sperm counts and motility are preserved or improved |
| Comparison with clomiphene2 | Enclomiphene is the trans-isomer of clomiphene. It is ~80% less likely to cause mood swings and fatigue than racemic clomiphene because it lacks the zuclomiphene isomer that accumulates in tissue |
| Duration of effect after discontinuation1 | Testosterone levels remain elevated for at least one week after stopping enclomiphene, suggesting a sustained HPG-axis effect |
| Regulatory status3 | Not FDA-approved as a finished drug product. Prescribed off-label and dispensed through compounding pharmacies. Considered investigational in the US; approved in some other jurisdictions |
Frequently Asked Questions
Is enclomiphene the same as clomiphene (Clomid)?
No. Enclomiphene is the trans-isomer of clomiphene. Clomid (racemic clomiphene) contains both the trans (enclomiphene) and cis (zuclomiphene) isomers. Zuclomiphene accumulates in tissue and is associated with mood changes and fatigue. Enclomiphene alone avoids this, making it better tolerated.
Is enclomiphene FDA-approved?
No. Enclomiphene is not FDA-approved as a finished drug product in the US. It is prescribed off-label and dispensed through licensed compounding pharmacies. It has been studied in Phase 3 trials and is approved in some other countries.
Will enclomiphene affect my fertility?
Enclomiphene is specifically used to preserve fertility. Unlike exogenous testosterone (which suppresses LH and FSH and causes testicular atrophy and azoospermia), enclomiphene stimulates LH and FSH, maintaining or improving sperm production.
How does enclomiphene compare to TRT?
TRT (injectable, topical, or oral testosterone) directly replaces testosterone but suppresses the HPG axis, causing testicular atrophy and infertility. Enclomiphene stimulates the HPG axis, preserving testicular function. TRT typically achieves higher testosterone levels; enclomiphene is preferred when fertility preservation is a priority.
- Earl JO et al. — Enclomiphene for secondary hypogonadism, 2019 · Earl JO, Bhatt D, Bhatt N, et al. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. Rev Urol. 2019;21(1):1–9.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.